Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 496,138
  • Shares Outstanding, K 118,410
  • Annual Sales, $ 164,520 K
  • Annual Income, $ -369,210 K
  • 60-Month Beta 1.78
  • Price/Sales 3.12
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:

Options Overview Details

View History
  • Implied Volatility 68.00%
  • Historical Volatility 39.60%
  • IV Percentile 6%
  • IV Rank 7.87%
  • IV High 248.67% on 01/08/21
  • IV Low 52.56% on 08/10/21
  • Put/Call Vol Ratio 0.05
  • Today's Volume 2,944
  • Volume Avg (30-Day) 3,989
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 52,430
  • Open Int (30-Day) 73,380

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.44
  • Low Estimate -0.54
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +44.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.14 +3.99%
on 10/18/21
4.91 -12.32%
on 09/27/21
-0.54 (-11.05%)
since 09/17/21
3-Month
4.06 +6.03%
on 08/19/21
5.28 -18.47%
on 07/21/21
-0.72 (-14.24%)
since 07/19/21
52-Week
4.06 +6.03%
on 08/19/21
11.10 -61.22%
on 02/08/21
-1.41 (-24.74%)
since 10/19/20

Most Recent Stories

More News
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis...

CLVS : 4.34 (+3.58%)
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

BMY : 57.57 (+1.11%)
PFE : 42.09 (+1.86%)
MRK : 79.35 (+2.85%)
CLVS : 4.34 (+3.58%)
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the AACR-NCI-EORTC...

CLVS : 4.34 (+3.58%)
Bet on Rising P/E Investing With These Top 5 Stocks

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

STKL : 7.89 (-3.07%)
LZB : 33.70 (+0.81%)
CLVS : 4.34 (+3.58%)
PULM : 0.7192 (+0.49%)
TPR : 38.46 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

3rd Resistance Point 4.54
2nd Resistance Point 4.45
1st Resistance Point 4.32
Last Price 4.34
1st Support Level 4.10
2nd Support Level 4.01
3rd Support Level 3.88

See More

52-Week High 11.10
Fibonacci 61.8% 8.41
Fibonacci 50% 7.58
Fibonacci 38.2% 6.75
Last Price 4.34
52-Week Low 4.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar